Deal struck for non-invasive prenatal test facility

Deal struck for non-invasive prenatal test facility

The Manchester company behind the IONA non-invasive prenatal test has signed an agreement to offer the ground-breaking treatment in Thailand.

Premaitha Health’s IONA, which detects Downs Syndrome and other genetic diseases in unborn children by using a blood sample, will be used in the Center for Medical Genomics at Ramathibodi Hospital, Mahidol University, partnering with the Thailand Center of Excellence for Life Sciences.

Due to its high level of accuracy, the IONA test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are both costly and resource intensive; and carry a small risk of miscarriage.

Dr Stephen Little, CEO of Premaitha, said: “We are delighted to have expanded our global footprint of laboratory customers to now include Thailand and that women in the country will increasingly be able to benefit from our safe and accurate non-invasive test. Asia Pacific is a region in which we believe there is significant potential for non-invasive prenatal testing – to secure our first operational laboratory in Asia is an important strategic milestone.”

See the article in full at TheBusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.